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Introduction
The construction of vectors targeting gene expression to specific sites in the organism is one of the current challenges in the field of gene therapy. In view of the fact that the efficient targeted transduction of genes still represents a major obstacle, the possibility of restricting gene expression to specific cell populations through specific promoters is of particular importance. [1] [2] [3] This not only applies to the treatment of systemic diseases, such as metastatic cancer, but also to local gene therapy, whose efficacy and safety can be improved by the use of cell type-specific promoters which keep the expression of the therapeutic gene in non-target cells at a minimum.
For these reasons, many of the recently described experimental gene therapy protocols make use of cell type-or tissue-specific promoters. [1] [2] [3] These include the tyrosinase promoter for directing gene expression to melanoma cells, [4] [5] [6] the ␣-fetoprotein promoter for hepatoma cells, 7 the mucin-1 promoter for mammary carcinoma, 8 the prostate-specific antigen promoter for prostate carcinoma 9 or the neuron-specific enolase promoter for neuronal cells. 10 In other studies, transcriptional control elements which can stimulate transcription in response to disease-specific alterations, such as hypoxic conditions 11 or the loss of cell cycle checkpoints in tumors, 12 have also been used. In these scenarios, promoters containing binding sites for hypoxia-inducible factor-1 (HIF-1) or the transcription factor E2F whose repression through the retinoblastoma protein pathway is lost in
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Received 20 May 1998; accepted 15 July 1998 most, if not all, tumor cells have been successfully incorporated into experimental gene therapy strategies. Furthermore, regulatory sequences inducible by therapeutic dose of ionizing radiation, such as the egr-1 promoter, 13 or in response to oncogenic lesions, such as the erbB2 promoter, 14 are worth mentioning in the same context. In addition to these promoters, a plethora of other potentially useful transcriptional regulatory sequences with a high degree of specificity has been described. [1] [2] [3] Some of these promoters appear to be ideally suited for gene therapy, because they combine strong transcriptional activity with a high degree of specificity. This is, for instance, true for the melanocyte-specific tyrosinase promoter. [4] [5] [6] 15 Frequently, however, specific promoters are inefficient activators of transcription which severely limits their applicability. A typical example is the von Willebrand factor (vWF) promoter, which exhibits a particularly high degree of endothelial cell (EC) specificity compared with other EC promoters, but is a poor activator of transcription [16] [17] [18] [19] (see also Results below). Other EC promoters are stronger, but less specific, such as the promoters for PECAM-1/CD31 20, 21 or flk-1/KDR. 22, 23 Another example is the promoter of the sucrase-isomaltase (SI) gene which is highly specific for intestinal cells and gastrointestinal tumors, 24, 25 but again is a poor transcriptional activator (see Results below). In the present study, we have chosen the vWF and SI promoters as models for the establishment of a strategy that would be suitable for enhancing the transcriptional activity of weak promoters without affecting their specificity (self-enhancing promoters). 26 This goal was achieved by incorporating into these promoters a positive feedback loop 26 provided by a chimeric transcription factor consisting of the strong herpes simplex virus VP16 transcriptional activation domain 27, 28 fused to the DNAbinding domain of LexA. 29 
Results
Comparative analysis of EC-specific promoters A comparison of different EC promoters in various ECs and non-endothelial cell lines was performed in order to identify a suitable promoter for the transcriptional targeting of ECs. The promoters of the human vWF, 17 PECAM-1 20, 21 and KDR 22 genes were analyzed in transient luciferase assays using human umbilical vein ECs (HUVECs), bovine aortic ECs (BAECs), mouse NIH3T3 fibroblasts and the human melanoma cell line MeWo. As shown in Figure 1a , a clear selectivity for ECs was found with all three promoters, with the highest degree of cell type specificity seen with the vWF promoter. This is particularly well documented by the data in Figure 1b which show a complete lack of activity in all non-endothelial cell lines tested (NIH3T3, MeWo, 10T1/2, HeLa), ie RLU values similar to those obtained with the promoterless basic vector, while both the PECAM-1 and KDR promoter showed readily detectable activities in the non-endothelial cells (Figure 1a ). We also tested other fragments of the KDR and PECAM-1 promoters (see Materials and methods for details), but these showed even lower levels of activity and/or specificity (data not shown). In contrast to its high degree of specificity, the vWF promoter is endowed with very poor transcriptional activation properties which severely limits its applicability (10-20% of SV40 promoter; Figure 1a) . In a first attempt to improve the activity of the vWF promoter we tested a construct in which the SV40 enhancer was placed upstream of the promoter. This construct (SV40EvWF) showed strongly increased transcriptional activity, but the cell type specificity was largely lost. We also tested other EC promoters, including those of the human endoglin (kindly provided by W. Graulich, IMT, Marburg, Germany) and human P-selectin 30 genes, but these did not provide the same high degree of specificity seen with the vWF promoter (data not shown). We did not include the preproendothelin promoter 31 in these studies because its activity has been reported to be restricted to bigger blood vessels and is also active in some epithelial cells, 32 which precludes its use for targeting the vasculature in tumors or other proliferative diseases.
Establishment of a positive feedback loop for the vWF promoter: proof of principle In view of the data discussed above, we sought to establish a new strategy that would allow for an enhancement of promoter activity by introducing a positive feedback loop. The basic principle of this strategy is to use a cell type-specific promoter to drive the simultaneous expression of the desired effector/reporter gene product and a strong artificial transcriptional activator, ie a chimeric protein consisting of the DNA-binding domain of LexA 29 and the strong herpes simplex virus VP16 transcriptional activation domain, 27, 28 which can stimulate transcription through LexA binding sites introduced into the promoter (Figure 2 ). To test the principle of this approach, we first used the vWF promoter as a model and performed transient luciferase assays after cotransfection of expression and reporter plasmids (see Figure 3a for details) into HUVECs, BAECs, NIH3T3 cells and MeWo cells. The data in Figure 3b (standardized to SV40 promoter activity (SP40p) for each cell line) and Figure 3c demonstrate that (1) the insertion of the seven LexA sites into the vWF promoter (LexvWFLuc) had no effect on activity or specificity; (2) the cotransfection of a SV40 promoter-driven expression vector encoding a VP16-LexA fusion protein (SV-VPLex) led to a dramatic increase in activity (approximately 30-to 70-fold), but the promoter also showed some activity in non-endothelial cells; (3) the coexpression of the same protein from the EC-specific vWF promoter resulted in a similar enhancement of transcription (23-to 66-fold), but expression was largely ECspecific (57-to 156-fold relative to NIH3T3; 29-to 78-fold relative to MeWo); and (4) cotransfection of a control vec- tor coding for a protein lacking the VP16 activation domain gave very low values similar to the transfection of the reporter alone. These observations constitute clear proof of principle. There are, however, several open questions that required further attention: (1) What is the reason for the observed EC selectivity after cotransfection of the reporter plasmid with the SV40 promoter-driven expression vector SV-VPLex (six-to 18-fold; see Figure 3c ), (2) would it be possible to endow the system with an even higher specificity; and (3) is the same approach also applicable to other cell type-specific promoters? All three issues will be addressed below.
Mechanism of cell type specificity
The relatively good EC selectivity after cotransfection of the reporter plasmid with the ubiquitous SV40 promoterdriven expression vector SV-VPLex points to the existence of a second mechanism conferring specificity on the promoter enhancement system established above (in addition to the cell type-specific feedback loop). This could in principle be due to two mechanisms: (1) a cell type-specific, promoter-independent function of the VP16 transactivation domain, which could be due to the existence of cell type-specific interacting modulators; or (2) the suppression of VP16 activity in non-endothelial cells in the context of a silent vWF promoter, eg due to the assembly of a promoter-bound protein complex which is unable to mediate, or actively represses, the activation function of VP16. In order to distinguish between these possibilities we constructed a reporter plasmid which, instead of a cell-type specific promoter, only contained a TATA-box and an initiator element (Inr) 33 downstream of seven LexA sites (LexTATA/ILuc; Figure 4a ). As expected, transfection of this construct on its own resulted in hardly any luciferase activity, while the cotransfection of SV-VPLex gave rise to a strong transcriptional activity (Figure 4b ). Most importantly, high activities were seen in both ECs and non-endothelial cells (MeWo and LoVo colon carcinoma cells), which clearly demonstrates that the activity of VP16 itself -at least in the systems analyzed -is not subject to cell type-dependent regulation. We therefore conclude that the transcriptional activation function of VP16 is dependent on the context of the promoter and suppressed through the vWF promoter in non-target cells.
Establishment of a single-vector system
The cotransfection protocol described above has the potential disadvantage that not all transduced cells receive an optimum molar ratio of promoter and transactivator which might lead to a sub-optimal activity and/or specificity. In addition, the requirement for two different plasmids would make it difficult to use the sys- tem with a vector suitable for in vivo gene therapy. We therefore decided to introduce all necessary components into a single plasmid vector using two different strategies. The first construct contains two copies of the vWF promoter, one directing the expression of VP16-LexA, the second being VP16-LexA-responsive and driving the transcription of the luciferase gene (construct vWF-2P in Figure 5a ). The second construct contains a single VP16-LexA-responsive promoter which directs the expression of a bicistronic transcript containing both the luciferase and VP16-LexA coding sequences separated by an internal ribosome entry site (IRES; construct vWF-I in Figure 5a) . 34 Both constructs were tested in HUVECs and BAECs, as well as in NIH3T3 and MeWo cells. vWF-2P was also analyzed in the non-endothelial cell lines PC-3 (human prostate carcinoma) and HepG2 (human hepatoma). As negative controls, we also constructed both vectors with a deletion of the VP16 domain (vWF-2P⌬VP and vWF-I⌬VP). From the data in Figure 5b and c, it is clear that the two promoter construct vWF-2P was superior with respect to promoter strength compared with the IRES-containing vector vWF-I. Thus, with respect to the wild-type vWF promoter, vWF-2P showed a 20-and 169-fold enhanced activity in BAECs and HUVECs, respectively ( Figure 5c ). As expected, the deletion of the VP16 moiety diminished the promoter activities to very low levels in both cases (Figure 5b ), proving the functionality of the VP16-dependent feedback loop. While the data on promoter strength (at least for vWF-2P) were similar to the results obtained by cotransfection (Figure 3c ), a substantial improvement was seen when the promoter specificities were compared. Thus, both single-plasmid systems were practically silent in non-endothelial cells, with values that were very similar to those obtained with the empty reporter plasmid. Although precise calculations are difficult, the promoter specificity was estimated to be 47-to Ͼ200-fold in BAECs and approximately 100-to Ͼ1000-fold in HUVECs compared with the other four cell lines (Figure 5c ).
Establishment of a positive feedback loop for the SI promoter Finally, we sought to verify the positive feedback loop system by applying it to a second cell type-specific promoter. Towards this end, we chose the promoter of the SI gene which is specifically active in crypt cells of the gut and in gastrointestinal tumor cells. 24, 25, 35 Appropriate plasmids were constructed (Figure 6a ) analogous to the vWF promoter system and tested by cotransfection into the colon carcinoma cell lines LoVo and CaCo-2, as well as the non-target cells NIH3T3 and MeWo. The following results were obtained with this system (Figure 6b and c): (1) the SI promoter was highly specific for colon carcinoma cells, but showed a very weak transcriptional activity (approximately 20% the activity of the SV40 promoter); (2) the insertion of the seven LexA sites upstream of the SI promoter (LexSILuc) had no significant effect on either activity or specificity; (3) the cotransfection of the SV40 promoter-driven expression vector SV-VPLex led to a dramatic increase in activity (approximately 30-to 40-fold), however, the promoter was also weakly activated in non-target cells; (4) the coexpression of the same protein from the cell specific SI promoter also resulted in a strong enhancement of transcription (14-to 37-fold), but in this case transcription was
Figure 5 Establishment of a one-vector system conferring an enhancement of EC-specific transcription. (a) Structure of the constructs. (b) Activity of the constructs shown in panel (a) after transient transfection of ECs and non-endothelial cells. ⌬VP, VP16 moiety deleted. Details were as described in the legend to Figure 1. (c) Quantitative evaluation of the data shown in panel (b).
specific for the colon carcinoma cells (Ͼ200-fold); and (5) cotransfection of a VP16-deleted control vector gave rise to similar values as seen with the reporter alone. These observations therefore clearly show that the colon carcinoma-specific activity of the SI promoter can be substantially increased by the system established in the present study. As in the case of the vWF promoter, the higher transcription in colon carcinoma cells observed with the SV40 promoter-driven expression vector SV-VPLex (see (3) above) appears to be due to promoter-specific suppression of the VP16 activation function in non-target cells, since no specificity was seen in LoVo cells with the TATA-Inr driven reporter plasmid LexTATA/ILuc (see Figure 4b ).
Discussion
A frequent problem with the generation of tissue-or cell type-specific vectors is the lack of promoters suitable for transcriptional targeting. A major reason lies in the fact that specific promoters are often relatively weak inducers of transcription. We have therefore decided to establish a strategy for the enhancement of the transcriptional activity of such promoters without losing the specificity. In the present study, we describe such a strategy and demonstrate its applicability to enhance the transcriptional efficiency of two weak cell type-specific promoters, the EC-specific vWF promoter 17 and the intestinal cellspecific SI promoter. 24 The principle of this strategy is the implementation of a positive auto-regulatory loop provided by a VP16-LexA fusion protein which is expressed simultaneously with the effector/reporter gene product and can bind to LexA sites inserted 5′ to the cell typespecific promoter (Figure 2 ). The feasibility of this approach was shown in cotransfection experiments, which showed an enhancement of transcriptional activity in the range of 23-to 67-fold for the vWF promoter, and 14-to 37-fold for the SI promoter. In spite of this dramatic increase in promoter activity, specificity was completely retained, and was in the order of 30-to 147-fold for the vWF promoter (Figure 3 ) and Ͼ200-fold for the SI promoter when compared to the activities in non-target cells ( Figure 6) .
Some of the data obtained in the experiments shown in Figures 3 and 6 suggest a second mechanism to be involved in conferring cell type specificity. Thus, expression of the VP16-LexA activator protein from the ubiquitous SV40 promoter resulted in a clearly cell type specific auto-regulatory loop. In order to address the basis of this observation we implemented the identical VP16-LexA-mediated feedback loop system into a ubiquitous basal promoter, TATA-Inr. In this case, the SV40-driven expression of VP16-LexA did not result in any cell type specificity, indicating that the VP16 protein itself is not subject to cell type-dependent modulatory mechanisms. This finding rather suggests that the vWF and SI promoters are able to suppress the action of a heterologous activator, such as VP16, in non-target cells where the promoter is silent. This scenario is supported by the observation that repression apparently plays a role in silencing the vWF promoter in non-endothelial cells. 19 A similar mechanism may operate in the case of the SI promoter, since we reproducibly observed a decrease in luciferase activities in non-target cells upon insertion of the SI promoter into the promoterless reporter plasmid pGL3.
We also investigated the effect of a positive auto-regulatory loop on a strong tissue-specific promoter, the melanocyte-specific tyrosinase promoter. 15 In this case, we also observed an increase in activity, but this enhancement was relatively modest (approximately two-fold; data not shown). Melanocyte-specific expression was not affected. These findings indicate that the promoter enhancement system in principle also works with the tyrosinase promoter, but that the increase in activity is rather poor presumably due to its strong activity in the wild-type form. We therefore anticipate that our strategy is particularly useful for enhancing the activity of weak promoters. In this context it will be interesting to investigate in future studies whether the same approach can also be used to increase the activity of promoters endowed with other kinds of specificity, such as cell cycle-controlled, mitogen-regulated, oncoproteininducible or hypoxia-responsive promoters.
The enhancement of transcription and promoter specificity were particularly impressive when all components of the positive feedback loop system were cloned into the same plasmid vector, which was demonstrated for the EC-specific activity of the vWF two-promoter construct vWF-2P (approximately 50-to Ͼ1000-fold relative to nonendothelial cells; Figure 5 ). We ascribe this result to an equal ratio of the transgene products in all transduced cells, a situation that cannot be achieved in cotransfection experiments. Surprisingly, a considerably reduced activity was seen when an IRES was used instead of the second promoter. A possible reason for this observation might be a less efficient expression of the VP16-LexA gene downstream of the IRES. We did not pursue this issue in view of the high activity and pronounced specificity of the two-promoter construct.
The functionality of the single plasmid system is of particular relevance when viral vectors are to be used for transduction. Viral vectors are currently the preferred means to achieve efficient transduction efficiencies in vivo. We are therefore currently in the process of generat-ing replication-deficient adenoviruses with a vWF promoter feedback loop to be able to investigate the activity and specificity of the positive feedback loop system in animal experiments. These experiments will also have to address the critical question as to whether the viral sequences will interfere with the transcriptional feedback loop of the inserted transgene.
Previous studies have shown that the natural vWF promoter is suitable to transduce a suicidal signal to ECs using the herpes simplex virus thymidine kinase/ganciclovir system after selection for transduced cells. 36 In view of the strong increase in promoter activity achieved by the system established in the present study it is very likely that the efficacy of such gene therapeutic approaches can be dramatically increased, especially if one takes into account the poor transfection efficiencies in vivo and that other effector systems can also be successfully used. In this context it is also relevant that a VP16-based transcriptional activator has been shown to be functional in vivo, 37 albeit in a different context. We therefore feel that the system established in the present study could represent an important step in the development of efficient genetic therapies.
Materials and methods

Cell culture
The mouse fibroblast cell lines NIH3T3 and 10T., and the human cell lines LoVo (ATCC CCL 229; colon carcinoma), CaCo-2 (ATCC HTB 37; colon carcinoma), HeLa (ATCC CCL 2; cervix carcinoma), PC-3 (ATCC CRL 1435; prostate carcinoma), HepG2 (ATCC HB 8065; hepatoma), and MeWo 38 (melanoma) were grown at 37°C in a humidified atmosphere of 5% CO 2 . PC-3 cells were maintained in RPMI 1640 (Boehringer Ingelheim BioProducts, Heidelberg, Germany) and the other cell lines in Dulbecco-Vogt modified Eagle's medium (DMEM; Boehringer Ingelheim BioProducts). RPMI 1640 and DMEM were supplemented with 10% fetal bovine serum (FBS; Life Technologies, Eggenstein, Germany) and 2 mm l-glutamine. MeWo cells were obtained from I Hart (London, UK) and LoVo cells from Hoechst Marion Roussell (Marburg, Germany). BAECs were kindly provided by W Risau (Bad Nauheim, Germany) and maintained in DMEM supplemented with 10% inactivated FBS (PAA Laboratories, Coelbe, Germany), and 2 mm l-glutamine. HUVECs were prepared by the method of Jaffe, 39 as modified by Thornton et al, 40 and cultivated in EGM-2 medium (Boehringer Ingelheim BioProducts).
Plasmids pGL3basic (basic), pGL3promoter (SV40p), and pGL3 control were purchased from Promega (Heidelberg, Germany). The basic construct lacking eukaryotic promoter and enhancer sequences was used for determining the vector-related background activity. The SV40p construct was used for standardizing transfection efficiencies. The luciferase constructs containing the human vWF promoter 17 (−487/+247), the human PECAM-1 promoter 20 (−50/+469 in Figure 1 , we also cloned the −939/+469, −228/+469 and +232/+469 fragments), the KDR promoter 22 (−225/+240 in Figure 1 , we also cloned the −780/+240 and −115/+240 fragments), and the SI promoter 24 (−175/+70) were cloned by PCR amplification using the listed oligonucleotides. The PCR products were digested with the corresponding restriction enzymes and ligated into the pGL3basic vector. The KDR promoter (−115/+240) construct was cloned using the intrinsic KpnI restriction site. The SV40EvWF construct containing the vWF promoter and SV40 enhancer was obtained by replacing the SV40 promoter of the pGL3control plasmid with the vWF promoter. LexvWFLuc, LexSILuc and LexTATA/ILuc contain seven LexA binding sites (5′-GTCGAGTACTGTATGTA-CATACAGTAC-3′) 29 inserted upstream of the promoters in the vWF and SI constructs or upstream of a synthetic TATA-box/initiator element 33 in pGL3. SV-VPLex was constructed by replacing the luciferase gene of pGL3 promoter with a fusion of the sequences encoding the nuclear localization signal (NLS) of the SV40 large T antigen and the transcriptional activation domain of the herpes virus protein VP16 (aa 411-455) to a cDNA fragment of the E. coli repressor LexA (aa 2-202) encoding its DNA binding domain. 29 PCR amplifications were performed using the oligonucleotides nVP16-5′, nVP16-3′ (template: pVP16; Clontech, Heidelberg, Germany), LexA-5′, and LexA-3′ (see below). The constructs vWF-VPLex and SIVPLex were obtained by replacing the SV40 promoter of SV-VPLex with the vWF promoter or the SI promoter. vWF-Lex and SI-Lex were cloned by inserting a PCRamplified fragment encoding the SV40 large T NLS fused to LexA (aa 2-202). For PCR amplification the oligonucleotides nLexA-5′ and LexA-3′ were used.
For cloning of vWF-2P and vWF-2P⌬VP, NotI/SalI digests of vWF-VPLex or vWF-Lex were converted to blunt ends and ligated into blunted, NotI-digested LexvWFLuc in a head-to-tail orientation. Two cloning steps were necessary to generate the vWF-I and vWF-I⌬VP constructs. Firstly, the IRES sequence of pIRES-EGFP (Clontech) was PCR amplified using the oligonucleotides IRES-5′ and IRES-3′ and cloned into the XbaI site of LexvWFLuc (the initiation ATG was reverted to the original position of the encephalomyocarditis virus). 34 Then, the NcoI/SalI fragments of the vWF-VPLex and vWF-Lex plamids were introduced into the IRESNcoI/SalI sites to give, respectively, the vWF-I and the vWF-I⌬VP constructs.
All plasmid DNAs were amplified in E. coli and purified according a standard protocol (Qiagen, Hilden, Germany). Plasmids obtained by PCR amplification were verified by DNA sequencing. The following oligonucleotides were used for PCR amplification (numbers refer to nucleotide positions, restriction sites are shown in italics): Transfections and luciferase assays NIH3T3, LoVo, CaCo-2, PC-3, HepG2, MeWo cells and BAECs (passage 10 to 14) were transfected at 50% confluency in six-well plates using the cationic liposome DOTAP as described by the manufacturer (Boehringer Mannheim, Mannheim, Germany). Three micrograms of plasmid (for cotransfection experiments 1 g of reporter plasmid and 2 g of activator plasmid or pUC19) were used per well and mixed with 6 l of DOTAP in transfection buffer. The transfection mixture was mixed with OptiMEM (Life Technologies) or EGM-2 (for BAECs) and added to the cells, followed by a 6-h incubation. 10T. and HeLa cells were transfected at 80% confluency by the DEAE-dextran technique. 41 HUVECs (passage 4 to 6) were transfected at 80% confluency with Superfect (Qiagen) following the manufacturer's protocol. 1.5 g plasmid (or 0.5 g reporter plasmid + 1 g activator plasmid or pUC19) and 9 l Superfect per well were mixed with serum-free DMEM and incubated for 2 h in EGM-2 on the cells. Luciferase activities were determined 40 h after replacement of the transfection medium with normal growth medium as decribed. 42 Transfections were performed in triplicates and repeated at least once using an independent plasmid preparation. The standard deviations were in the range of 5-20%. We did not use a second cotransfected plasmid for standardization, because in previous experiments we found that all ubiquitous promoters (including SV40 and CMV) are more or less influenced by cotransfected plasmids, in particular those encoding (domains of) transcription factors, and can sometimes also affect the activity of the regulatory sequences to be tested. This may result in an incorrect standardization. We therefore feel that it is more appropriate to transfect the reference plasmid separately and to perform each assay several times to control for experimental variation.
